CLRB news

Latest 1 stories · newest Nov 10, 2026

CLRB

Cellectar Reports Q3 26 Results, Updates Iopofosine I 131 Roadmap

Cellectar Biosciences announced financial results and corporate updates, highlighted by new efficacy data supporting accelerated approval for iopofosine I 131 and a plan to file an NDA in the first half of 2027.

Earnings Nov 10, 2026 sentiment +0.50 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same CLRB feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/CLRB/newsSTART FREE